BM histologic features of patients with FPDMM
| . | All (N = 55) . | Adult (n = 24) nonmalignant . | Pediatric (n = 21) nonmalignant . | Adult malignant (n = 7) . | Pediatric malignant (n = 3) . |
|---|---|---|---|---|---|
| Marrow cellularity | |||||
| Hypercellular | 7 (12.7%) | 0 (0%) | 0 (0%) | 4 (57.1%) 1 CMML, 1 MDS, and 2 AML | 3 (100%) 1 T-ALL, 1 B-ALL, and 1 AML |
| Hypocellular | 30 (54.5%) | 13 (54.2%) | 17 (81%) | 0 (0%) | 0 (0%) |
| Normocellular | 18 (32.7%) | 11 (45.8%) | 4 (19.0%) | 3 (42.9%) 1 SMM and 2 MDS | 0 (0%) |
| Megakaryocyte quantity | |||||
| Normal number | 30 (54.5%) | 18 (75%) | 9 (42.9%) | 3 (42.9%) 1 SMM and 2 MDS | 0 (0%) |
| Increased number | 12 (21.8%) | 5 (20.8%) | 4 (19.0%) | 3 (42.9%) 1 CMML, 1 AML, and 1 MDS | 0 (0%) |
| Decreased number | 7 (12.7%) | 0 | 3 (14.3%) | 1 (14.3%) 1 AML | 3 (100%) 1 T-ALL, 1 B-ALL, and 1 AML |
| Dysmegakaryopoiesis | 42 (76.4%) | 23 (95.8%) | 14 (66.7%) | 5 (71.4%) 3 MDS and 2 AML | NE |
| Multilineage dysplasia | 3 (5.5%) | 0 (0%) | 0 (0%) | 3 (42.9%) 1 CMML, 1 AML, and 1 MDS | NE |
| Increased blasts (5%-19%) | 2 (3.6%) | 0 (0%) | 0 (0%) | 2 (28.6%) 1 CMML and 1 MDS | 0 |
| Increased blasts (>20%) | 5 (9.1%) | 0 (0%) | 0 (0%) | 2 (28.6%) 2 AML | 3 (100%) 1 T-ALL, 1-B-ALL, and 1 AML |
| BM diagnosis | |||||
| Nonmalignant | 45 (81.8%) | 24 | 21 | ||
| MDS | 3 (5.5%) | 3 (42.9%) | |||
| AML | 3 (5.5%) | 2 (28.6%) | 1 (33.3%) | ||
| CMML | 1 (3.6%) | 1 (14.3%) | |||
| T-ALL | 1 (1.8%) | 1 (33.3%) | |||
| B-ALL | 1 (1.8%) | 1 (33.3%) | |||
| SMM | 1 (1.8%) | 1 (14.3%) |
| . | All (N = 55) . | Adult (n = 24) nonmalignant . | Pediatric (n = 21) nonmalignant . | Adult malignant (n = 7) . | Pediatric malignant (n = 3) . |
|---|---|---|---|---|---|
| Marrow cellularity | |||||
| Hypercellular | 7 (12.7%) | 0 (0%) | 0 (0%) | 4 (57.1%) 1 CMML, 1 MDS, and 2 AML | 3 (100%) 1 T-ALL, 1 B-ALL, and 1 AML |
| Hypocellular | 30 (54.5%) | 13 (54.2%) | 17 (81%) | 0 (0%) | 0 (0%) |
| Normocellular | 18 (32.7%) | 11 (45.8%) | 4 (19.0%) | 3 (42.9%) 1 SMM and 2 MDS | 0 (0%) |
| Megakaryocyte quantity | |||||
| Normal number | 30 (54.5%) | 18 (75%) | 9 (42.9%) | 3 (42.9%) 1 SMM and 2 MDS | 0 (0%) |
| Increased number | 12 (21.8%) | 5 (20.8%) | 4 (19.0%) | 3 (42.9%) 1 CMML, 1 AML, and 1 MDS | 0 (0%) |
| Decreased number | 7 (12.7%) | 0 | 3 (14.3%) | 1 (14.3%) 1 AML | 3 (100%) 1 T-ALL, 1 B-ALL, and 1 AML |
| Dysmegakaryopoiesis | 42 (76.4%) | 23 (95.8%) | 14 (66.7%) | 5 (71.4%) 3 MDS and 2 AML | NE |
| Multilineage dysplasia | 3 (5.5%) | 0 (0%) | 0 (0%) | 3 (42.9%) 1 CMML, 1 AML, and 1 MDS | NE |
| Increased blasts (5%-19%) | 2 (3.6%) | 0 (0%) | 0 (0%) | 2 (28.6%) 1 CMML and 1 MDS | 0 |
| Increased blasts (>20%) | 5 (9.1%) | 0 (0%) | 0 (0%) | 2 (28.6%) 2 AML | 3 (100%) 1 T-ALL, 1-B-ALL, and 1 AML |
| BM diagnosis | |||||
| Nonmalignant | 45 (81.8%) | 24 | 21 | ||
| MDS | 3 (5.5%) | 3 (42.9%) | |||
| AML | 3 (5.5%) | 2 (28.6%) | 1 (33.3%) | ||
| CMML | 1 (3.6%) | 1 (14.3%) | |||
| T-ALL | 1 (1.8%) | 1 (33.3%) | |||
| B-ALL | 1 (1.8%) | 1 (33.3%) | |||
| SMM | 1 (1.8%) | 1 (14.3%) |
SMM, smoldering multiple myeloma.